Katrine L. Wallace, PhD

From the Field

Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer

05/19/2022

Junxin Shi , PhD;

Yiqiong Xie , PhD, MPH;

Katrine L. Wallace , PhD;

Robert Reid , MD;

Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.

Dr Wallace and colleagues...

05/19/2022

Journal of Clinical Pathways

Research Reports

Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer

06/05/2023

Scott H. Bunner , MPH;

Allison M. Saiz , MD;

Nicole M. Engel-Nitz , PhD;

Emma L. Barber , MD;

Katrine L. Wallace , PhD;

Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.

Emma L. Barber, MD, and...

06/05/2023

Journal of Clinical Pathways